Sintilimab: First Global Approval

No abstract is available for this paper.

• Publication year

  2019

• Venue

  Drugs

• Publication date

  2019-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s40265-019-1066-zPMID 30742278
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial.

  2019cited by this paper
• Hodgkin lymphoma: 2018 update on diagnosis, risk‐stratification, and management

  2018cited by this paper
• Next generation of immune checkpoint therapy in cancer: new developments and challenges

  2018cited by this paper
• A first-in-human phase 1a trial of sintilimab (IBI308), a monoclonal antibody targeting programmed death-1 (PD-1), in Chinese patients with advanced solid tumors.

  2018cited by this paper
• Preclinical characterization of Sintilimab, a fully human anti-PD-1 therapeutic monoclonal antibody for cancer

  2018cited by this paper
• Efficacy and Safety of Sintilimab Combined with 1st Line Chemotherapy in Advanced Squamous Cell Non‐small Cell Lung Cancer: OA08

  2018cited by this paper
• Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma.

  2017cited by this paper

• Efficacy and safety of sintilimab in the treatment of sqNSCLC

  2026cites this paper
• Integrating molecular and immune biomarkers for precision therapy in hepatitis B: Associated hepatocellular carcinoma

  2026cites this paper
• Differential Diagnosis between Sintilimab-related Autoimmune Myocarditis and Acute Myocardial Infarction.

  2026cites this paper
• The clinical trial landscape of colorectal cancer liver metastases: profile analysis and target prediction

  2026cites this paper
• Health-related quality of life and symptoms in patients with previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer treated with sintilimab or placebo plus pemetrexed and platinum (ORIENT-11): A randomized, double-blind, phase 3 trial.

  2025cites this paper
• Effects of Shenqi Xiangyi granules in advanced gastric cancer chemotherapy

  2025cites this paper
• Transarterial chemoembolization combined with lenvatinib and sintilimab vs lenvatinib alone in intermediate-advanced hepatocellular carcinoma

  2025cites this paper
• Recombinant human‑endostatin combined with sintilimab and chemotherapy in first‑line treatment of locally advanced or metastatic esophageal squamous cell carcinoma

  2025cites this paper
• Sintilimab for the treatment of lung adenocarcinoma-induced immune-related hypophysitis: a case report

  2025cites this paper
• Fruquintinib Plus Sintilimab in Patients with Treatment-Naive and Previously Treated Advanced Renal Cell Carcinoma: Results from a Phase Ib/II Clinical Trial

  2025cites this paper
• Combining anti-PD-1 antibodies with surufatinib for gastrointestinal neuroendocrine carcinoma: Two cases report and review of literature

  2025cites this paper
• Research progress of sintilimab in the treatment of cancer (Review)

  2025cites this paper
• Case Report: A rare case of sintilimab-induced dermatomyositis in a patient with gastric cancer

  2025cites this paper
• Partial response to posterior line immunotherapy for more than 15 months in a pMMR patient with cutaneous metastasis of rectal carcinoma: a case report

  2025influential citation
• Meta-Analysis of the Efficacy and Safety of Sintilimab in Combination With Chemotherapy for Advanced Non–Small-Cell Lung Cancer

  2025cites this paper
• Combination therapy of TKIs and ICIs for the treatment of anaplastic thyroid carcinoma

  2025cites this paper
• Unravelling T cell exhaustion through co‐inhibitory receptors and its transformative role in cancer immunotherapy

  2025cites this paper
• Real-world study of efficacy and safety of PD-1 antibody monotherapy and combination therapy in pediatric lymphoma patients

  2025cites this paper
• Case Report: Guselkumab treatment for sintilimab-exacerbated psoriasis in a cancer patient

  2025cites this paper
• Targeting Immune Checkpoints: Basic Signaling Pathways and Clinical Translation in Cancer Therapeutics

  2025cites this paper
• Sintilimab-induced intestinal obstruction and hemorrhage of the digestive tract: a case report

  2025cites this paper
• Sintilimab Plus Axitinib for Advanced Fumarate Hydratase-Deficient Renal Cell Carcinoma: A Phase 2 Nonrandomized Clinical Trial.

  2025cites this paper
• From Innovation to Complication: A Case Report and Review on Immune-Related Colitis Induced by ICIs

  2025cites this paper
• Integration of humanized ROBO1 CAR in PD-1 locus in natural killer cells delivers synergistic tumor-killing effect against non-small cell lung cancer

  2025cites this paper
• Targeted drug delivery systems in Lymphoma treatment: Advances and clinical perspectives.

  2025cites this paper
• Liquid Biopsy in Hematologic Malignancies: Advances, Challenges, and Future Directions.

  2025cites this paper
• Real-world efficacy assessment for sintilimab in recurrent or metastatic cervical cancer

  2025cites this paper
• Case Report: Multiple cutaneous keratoacanthoma-like lesions in a colorectal cancer patient treated with sintilimab

  2025cites this paper
• Brief insight into the in silico properties, structure-activity relationships and biotransformation of fruquintinib, an anticancer drug of a new generation containing a privileged benzofuran scaffold.

  2024cites this paper
• Current trends in sensitizing immune checkpoint inhibitors for cancer treatment

  2024cites this paper
• Immune-related adverse events with renal colic as the main manifestation: a case report of sintilimab-induced ureteritis/cystitis treated by ureteral stent and review of the literature

  2024cites this paper
• Immune checkpoints in B-cell Lymphoma: Still an Unmet challenge from Basic research to clinical practice.

  2024cites this paper
• Pembrolizumab versus sintilimab in patients with advanced NSCLC: a retrospective multicenter study with propensity-score matching analysis

  2024cites this paper
• Case Report: Efficacy of anlotinib and sintilimab in treating lung adenocarcinoma with RET fusion and PD-L1 expression

  2024cites this paper
• Adverse skin reactions secondary to sintilimab for advanced gastric adenocarcinoma: A case report and literature review

  2024cites this paper
• PD-1 inhibitor sintilimab treated patients with metastatic triple-negative breast cancer

  2024cites this paper
• Current insights and future directions of Li-Fraumeni syndrome

  2024cites this paper
• Combination kinase inhibitors and immunotherapy for unresectable anaplastic thyroid carcinoma: A retrospective single-center study.

  2024cites this paper
• Inhibition of PCSK9: A Promising Enhancer for Anti-PD-1/PD-L1 Immunotherapy

  2024cites this paper
• The Trend of the Treatment of Advanced Hepatocellular Carcinoma: Combination of Immunotherapy and Targeted Therapy

  2024cites this paper
• Studying protein-protein interactions: Latest and most popular approaches.

  2024cites this paper
• Etoposide, cisplatin, and sintilimab combined with anlotinib in successful treatment of adrenocortical carcinoma with lung metastasis: a case report

  2024cites this paper
• Case report: A sustained survival benefit of third-line immunotherapy for refractory thymic carcinoma

  2024cites this paper
• Immune myocarditis induced by sintilimab therapy: A case report

  2024cites this paper
• Minimally invasive intervention combined with targeted immunotherapy achieves complete clinical response in advanced colorectal cancer: a case study and literature review

  2024cites this paper
• Kikuchi disease: A case report about Sintilimab-induced Kikuchi histiocytic necrotizing lymphadenitis and literature review

  2024cites this paper
• Partial remission with sintilimab monotherapy in a patient carrying a CD274 amplification in refractory diffuse large B‑cell lymphoma: A case report

  2024influential citation
• Cancer drug indication approvals in China and the United States: a comparison of approval times and clinical benefit, 2001–2020

  2024cites this paper
• Risk factors and outcomes of pericardial effusion in cancer patients receiving PD-1 inhibitors.

  2024cites this paper
• Immune checkpoint inhibitors in the treatment of hepatocellular carcinoma

  2024cites this paper
• Long-Term Follow-Up of Combination Therapy with Sintilimab and Anlotinib in Gallbladder Follicular Dendritic Cell Sarcoma: A Rare Case Report

  2024cites this paper
• Anlotinib plus Sintilimab achieved in an antitumor effect of complete remission in a patient with advanced hepatocellular carcinoma: a case report

  2024cites this paper
• Dramatic response of a negative PD-L1 expression and TMB low pulmonary sarcomatoid carcinoma to sintilimab combined with anlotinib

  2023cites this paper
• Diagnostic Challenges in PD-1 Inhibitor Induced Panuveitis in a Teenage Girl with Chest Soft Tissue Sarcoma - A Case Report

  2023cites this paper
• Lichenoid mucocutaneous reactions associated with sintilimab therapy in a non-small cell lung adenocarcinoma patient: case report and review

  2023cites this paper
• Immune checkpoint inhibitor-associated adrenal insufficiency in Chinese cancer patients: a retrospective analysis

  2023cites this paper
• Evaluation of Chelator-to-Antibody Ratio on Development of 89Zr-iPET Tracer for Imaging of PD-L1 Expression on Tumor

  2023cites this paper
• Sintilimab plus fluorouracil, leucovorin, oxaliplatin and docetaxel regimen as neoadjuvant therapy for resectable gastric cancer and biomarker exploration.

  2023cites this paper
• Efficacy and safety of sintilimab combined with apatinib as third-line or above therapy for patients with advanced or metastatic gastric cancer

  2023cites this paper
• Toxic Epidermal Necrolysis and Stevens - Johnson Syndrome Following Sintilimab Administration in a Non-Small Cell Lung Cancer Patient: A Case Report

  2023cites this paper
• Sintilimab-induced inflammatory myopathy in a patient with esophageal cancer: a case report

  2023cites this paper
• A rare presentation of Sintilimab-induced swelling along the vessels: Case report

  2023cites this paper
• Safety and clinical efficacy of sintilimab (anti-PD-1) in pediatric patients with advanced or recurrent malignancies in a phase I study

  2023cites this paper
• Sintilimab plus anlotinib as second‐ or third‐line therapy in metastatic non‐small cell lung cancer with uncommon epidermal growth factor receptor mutations: A prospective, single‐arm, phase II trial

  2023influential citation
• Literature Analysis of 53 Cases of Sindilizumab-Induced Adverse Drug Reactions

  2023cites this paper
• Sintilimab-induced Alopecia Universalis in a Patient With the Anti-tumor Effect of Complete Remission After Hepatectomy

  2023cites this paper
• A case of toxic epidermal necrolysis associated with lenvatinib and sintilimab therapy for intrahepatic cholangiocarcinoma

  2023cites this paper
• Radiographic and α-fetoprotein response predict pathologic complete response to immunotherapy plus a TKI in hepatocellular carcinoma: a multicenter study

  2023cites this paper
• Inside PD-1/PD-L1,2 with their inhibitors.

  2023cites this paper
• BODIPY-Based NO Probe for Macrophage-Targeted Immunotherapy Response Monitoring.

  2023cites this paper
• Hot and cold tumors: Immunological features and the therapeutic strategies

  2023cites this paper
• Concurrent sintilimab with sequential chemoradiotherapy for unresectable, stage III non-small cell lung cancer: a retrospective study

  2023cites this paper
• A case of subclinical immune checkpoint inhibitor-associated myocarditis in non-small cell lung cancer

  2023cites this paper
• Anlotinib succeeded in rescue therapy for hyperprogression induced by immune checkpoint inhibitors: a case report.

  2023cites this paper
• Advances in the structural characterization of complexes of therapeutic antibodies with PD-1 or PD-L1

  2023cites this paper
• Anlotinib combined with Sintilimab is win-win cooperation for primary squamous cell carcinoma of the thyroid: A case report and literature review

  2023cites this paper
• Case report: Bullous pemphigoid associated with sintilimab therapy for pMMR/MSS colorectal cancer

  2023cites this paper
• Successful treatment of immune-related lichenoid dermatitis by Weiling decoction in a patient with non-small cell lung cancer: A case report and review of literature.

  2023cites this paper
• Conversion Therapy with Sintilimab for dMMR/MSI-H Stage III Colon Cancer: A Case Report and Literature Review

  2023cites this paper
• Sintilimab plus chemotherapy for first-line treatment of advanced or metastatic nonsquamous non-small-cell lung cancer: network meta-analysis.

  2023cites this paper
• Corneal ulcer development due to sintilimab-anlotinib combination therapy-induced dry eye: a case report

  2023cites this paper
• Case report: A rare case of sintilimab-induced gastric stenosis and literature review

  2023cites this paper
• Cost-effectiveness of sintilimab plus chemotherapy versus chemotherapy alone as first-line treatment of locally advanced or metastatic oesophageal squamous cell carcinoma

  2023cites this paper
• Combined iodine-125 seed strand, portal vein stent, transarterial chemoembolization, lenvatinib and anti-PD-1 antibodies therapy for hepatocellular carcinoma and Vp4 portal vein tumor thrombus: A propensity-score analysis

  2023cites this paper
• Late‑onset immune checkpoint inhibitor‑related pneumonitis after cessation of sintilimab: A case report and literature review.

  2023cites this paper
• Sintilimab combined with chemotherapy successfully treated a patient with advanced submandibular gland tumor.

  2023cites this paper
• Application of immune checkpoint inhibitors in immunotherapy for gastric cancer.

  2023cites this paper
• Systemic Therapy in Advanced Hepatocellular Carcinoma: Patient Selection and Key Considerations

  2022cites this paper
• Optimal target saturation of ligand-blocking anti-GITR antibody IBI37G5 dictates FcγR-independent GITR agonism and antitumor activity

  2022cites this paper
• Toxic epidermal necrolysis associated with chemoimmunotherapy for lymphoma: case report and literature review.

  2022cites this paper
• Fruquintinib in Combination With PD-1 Inhibitors in Patients With Refractory Non-MSI-H/pMMR Metastatic Colorectal Cancer: A Real-World Study in China

  2022cites this paper
• Sintilimab-induced autoimmune diabetes: A case report and review of the literature

  2022cites this paper
• Cisplatin plus anti-PD-1 antibody enhanced treatment efficacy in advanced esophageal squamous cell carcinoma.

  2022cites this paper
• Revolutionization in Cancer Therapeutics via Targeting Major Immune Checkpoints PD-1, PD-L1 and CTLA-4

  2022cites this paper
• Recent advances of nanodrug delivery system in the treatment of hematologic malignancies.

  2022cites this paper
• Successful treatment of immune-related cystitis by Chai-Ling-Tang (Sairei-To) in a gastric carcinoma patient: Case report and literature review.

  2022cites this paper
• Treatment of PD-1 Inhibitor-Associated Toxic Epidermal Necrolysis: A Case Report and Brief Review

  2022cites this paper
• Sintilimab for the treatment of non-small cell lung cancer

  2022cites this paper
• Streamlining the Transition From Yeast Surface Display of Antibody Fragment Immune Libraries to the Production as IgG Format in Mammalian Cells

  2022cites this paper
• Management of Non-Small Cell Lung Cancer: Updates from the European Lung Cancer Congress 2022

  2022cites this paper